Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial (Q41044036)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 April 2015

Language	Label	Description	Also known as
English	Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial	scientific article published on 20 April 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Gordon Charles Cook

object named as

Gordon Cook

9

0 references

object named as

Mark Cook

10

0 references

object named as

Cathy Williams

5

0 references

4

object named as

Kwee Yong

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

author name string

Steve Schey

1

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Sarah R Brown

2

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Avie-Lee Tillotson

3

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Faith Davies

6

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Gareth Morgan

7

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Jamie Cavenagh

8

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Guillermo Orti

11

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Curly Morris

12

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Debbie Sherratt

13

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Louise Flanagan

14

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Walter Gregory

15

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

James Cavet

16

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Myeloma UK Early Phase Clinical Trial Network

17

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

language of work or name

0 references

publication date

20 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

170

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

336-348

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Treatment options for relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Lenalidomide after stem-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Bendamustine in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

A flexible design for multiple armed screening trials

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13435

21 January 2018

Identifiers

10.1111/BJH.13435

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Microsoft Academic ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

2-s2.0-84942097336

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41044036&oldid=1913609262"